Fresenius Medical Care AG Advances Second Tranche of Share‑Buyback Programme
On 30 March 2026, Fresenius Medical Care AG (FMC) announced the continuation of its share‑buyback programme, specifically the second tranche of the initiative. Between 23 and 27 March, FMC repurchased a total of 8.98 million shares through a series of transactions executed by a credit institution on the company’s behalf.
Transaction Details
| Item | Value |
|---|---|
| Shares repurchased | 8.98 million |
| Period | 23–27 March 2026 |
| Weighted‑average price | Stable, with a modest upward trend observed across the week |
| Trading venues | Main German exchange (Frankfurt XETRA) and additional regional European markets |
The buyback was conducted at weighted‑average prices that remained largely stable throughout the reporting period. A slight upward trend in the purchase price was noted, reflecting the dynamic nature of the European equities markets during that week.
Regulatory Compliance
The announcement complies with the disclosure requirements of Regulation (EU) No. 596/2014 and its delegated regulation. FMC will continue to provide updates on the progression of the buyback programme on its investor relations website, ensuring that shareholders receive timely and accurate information regarding the company’s capital‑market activities.
Strategic Context
No additional strategic or financial initiatives were disclosed in the communication. FMC’s decision to advance the buyback programme aligns with its broader shareholder‑value strategy, aiming to optimize capital structure and enhance return metrics for investors.
Implications for Stakeholders
- Shareholders: The continuation of the buyback programme may support share price stability and potentially improve earnings per share metrics.
- Capital Markets: The consistent execution of buyback transactions reflects FMC’s disciplined approach to capital allocation.
- Regulatory Oversight: Adherence to EU disclosure regulations underscores FMC’s commitment to transparency and governance standards.
The company remains committed to maintaining open communication with its investors and will provide further details as the programme progresses.
